Podcasts about hcv

Steven Henke is the Chief of Brand Marketing at DAP Health. DAP Health (DAP) is an advocacy-based health center in Palm Springs, CA, serving over 8,000 patients, offering medical and mental healthcare, STI testing and treatment, dentistry, pharmacy, and lab. A variety of wraparound services enable patients to experience optimal health, including social services, support groups, alternative therapies, and other wellness services. DAP opened one of California's first COVID clinics and hotlines to offer screening, testing, and treatment. DAP is also working to address social determinants of health that are causing negative health outcomes during this pandemic, like food and housing insecurity, joblessness, isolation, and access to ongoing healthcare.DAP's sexual health clinic offers STI testing and treatment, Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), and HIV and HCV testing. DAP has also earned Charity Navigator's highest rating for the twelfth consecutive year—landing DAP in the top 6% of nonprofits rated. At DAP, Steven plans and implements brand marketing and PR strategies with various stakeholder communities, including businesses, chambers of commerce, volunteers, donors, retail, and media. Steven's primary areas of focus include visual, written, and digital storytelling on behalf of DAP Health, Revivals Stores, Resource Development events, annual giving, major gifts, planned giving, and capital campaign communications.Here, Steven shares how DAP's Revivals Stores serve as a “gateway drug” to life-changing healthcare services. He dives into his career journey from working part-time retail jobs, landing a position at Target Corporate, and eventually making his way to DAP in Palm Springs. Steven also shares details about the annual Revivals After Dark event, how he curates the furniture collection at each store, and the most unique and noteworthy donations. MC Design Academy is designed to be a space where I get to share my expertise with you, where you'll get to learn all about visual merchandising, design, display, retail, and everything in between. Come along as I practice my craft and be sure to like, subscribe, and follow our socials to keep updated. See you in the merchandising land of MC Design Academy!What's Inside: How DAP's Revivals Stores introduce customers to life-changing healthcare servicesHow Steven curates the furniture collections at each Revivals locationStories about some of the most unique donations at RevivalsMentioned In This Episode:DAP Health on InstagramDAP Health on FacebookRevival Stores on InstagramRevivalsstores.comRevivals Stores on FacebookRevivals Stores on YouTube

This weekend's Newsmaker, Indiana University hepatologist and key opinion leader Naga Chalasani, joins Roger Green to discuss Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting, an article his group published recently in Hepatology Communications. He shares highlights from the paper and points out the one key area in which his group found room for improvement in their initial protocol. Naga and colleagues wrote this paper after learning from Madrigal Pharmaceuticals that they were among the largest early prescribers of resmetirom and, relative to others, had achieved reimbursement with virtually all their patients and a high percentage of patients actually starting the medication. After receiving requests from other states for advice, the group decided to author this paper.In the paper, Naga and colleagues focused on patient selection, care pathway, how IUHealth got the medicine to their patients, and experience with safety and tolerability.In the paper, Naga and colleagues discuss their experiences in prescribing resmetirom for 113 patients in the first seven months after resmetirom's approval. Of these, IUHealth succeeded in achieving reimbursement for 110 of them. Of these patients, 83 initiated therapy, and 16% of those discontinued. In this interview, Naga shares some of the decisions that made the group so successful in the first three areas and identifies one subsequent area where the group found an opportunity for improvement: systematic follow-up with patients after prescribing. He attributes the 16% discontinuation rate to a "prescribe and forget" policy, similar to one that was successful in HCV, where clinicians prescribed without systematic follow-up until blood levels were obtained three months later. With a "prescribe and follow up" policy that includes phone calls at 1 and 3 months, he anticipates discontinuation rates will fall to something akin to the 5% rate in Phase 3 trials. What makes this interview so fascinating is Naga's description of the thinking that went behind specific decisions the group made in terms of patient management and pathway and suggests other options that might work as well. In all, this interview provides an excellent guide for clinics and providers on how to best integrate resmetirom into their practices.

As the world aims to eradicate Hepatitis C (HCV) by 2030, Carrielynn Lund and Dr. Alexandra King's team created Journeys to Wellness: Prairie Hepatitis C Roadmap — a step-by-step guide to tackling a spike of new infections across the prairies. Hepatitis C causes severe liver disease, and was notoriously difficult to treat until the introduction of direct-acting antivirals a decade ago — antivirals which boast a remarkable 95% success rate. Despite this advancement, Lund and Dr. King say Saskatchewan, Alberta and Manitoba need to know why HCV cases keep rising, particularly in jails, in remote communities, and in people who lack adequate housing and nutrition. Even so, the virus is not picky, as Carrielynn Lund learned when she was first diagnosed in the 1990s. Her doctor wrongly told her back then the blood-borne illness could be spread only through injection drug use. Shocked, Lund said “I went out of that room and drove home thinking, oh my God, I'm gonna die.” A single mother of two, she resumed her professional life and never disclosed that “dark, dirty secret” until nearly 20 years later, when she became friends with Dr. King. The Waniska team led by Saydi Harlton brought together researchers, health professionals, and people who've lived with hepatitis C in sharing circles, workshops and interviews. “The stigma around this needed to be addressed and I wanted to be a part of it,” said Lund. “People often feel really alone in this journey, and it's so important that we create spaces where they can share their stories and be heard,” Lund says As participants painted stones to represent their journey, many of them identified barriers to care, including confidentiality breaches, misinformation and inadequate access to testing. “My priority right now may or may not be my hepatitis C. It might be, where am I going to sleep today? Or, you know what? What food am I going to be getting?” said Dr. King. In the Roadmap she said the disproportionately high number of cases in Indigenous people shows a need for true elimination strategies, rather than pockets of “little pilot projects.” "There aren't necessarily a lot of resources, so you're dealing with fairly fragile systems," Dr. King noted. Recent provincial government decisions to axe needle exchanges, and cut public transportation routes to remote and northern communities have taken their toll, she added. Given the hurdles Indigenous and two-spirited people face, both Dr. King and Lund say prairie people need culturally informed care, and Indigenous-led hepatitis C elimination strategies with predictable funding and resources.   “It really helps you to understand the importance of really good evidence-based policy that supports people and meet them where they're at,” Dr. King said. Lund and Dr. King believe making a fiscal case for early detection and treatment may also swing policy-makers back toward patient-centred care. Peer support also plays a part, Lund said. “When someone who has been through it helps a newly diagnosed person, it can truly change everything for them," she said.  

Join us in this episode as we explore the groundbreaking Medication for Addiction Treatment (MAT) Order Set at UC San Diego Health. This innovative system helped them earn CHIME's top "Digital Health Most Wired" Level 10 status in 2024. What You'll Learn: The motivation behind the creation of UC San Diego's MAT Order Set. How interdisciplinary collaboration led to a comprehensive care model. Implementation details and integration of additional screenings. Data demonstrating reduced hospital readmissions and increased buprenorphine usage. Challenges and lessons learned during the implementation process. Educational impacts on medical resident training and future directions. MODERATOR: Gregory R. Polston, MD Clinical informaticist, Associate Medical Director, Center for Pain Medicine, UC San Diego Health Section Chief of the pain service, VA Medical Center La JollaBio: Dr. Polston is a board-certified anesthesiologist with expertise in pain medicine and clinical informatics at UC San Diego Health. He serves as Associate Medical Director at the Center for Pain Medicine and Section Chief of the pain service at the VA Medical Center La Jolla. Dr. Polston specializes in opioids and risk monitoring for acute and chronic pain, promoting a comprehensive approach to pain management that involves patient engagement and diverse therapeutic methods. His research focuses on chronic opioid therapy, placebos, and electronic medical records.GUEST: Laura Bamford, MD, MSCE Clinical Professor of Medicine Division of Infectious Diseases and Global Public Health Clinical Professor of Medicine Medical Director Owen Clinic Co-Director Clinical Investigations Core San Diego Center for AIDS Research Division of Infectious Diseases and Global Public Health University of California, San Diego Bio: Laura completed her Internal Medicine residency at Columbia University Medical Center and Infectious Diseases fellowship at the Hospital of the University of Pennsylvania where she also received a Master of Science in Clinical Epidemiology. She's a Clinical Professor of Medicine in the Division of Infectious Diseases and Global Public Health and Medical Director of the HIV Medicine Owen Clinic. Her clinical and research interests include HIV and HCV treatment and prevention in people who use drugs. She's passionate about delivering patient-centered care and research with a low barrier and harm reduction approach. With funding from the Ryan White HIV/AIDS Program Part F Special Projects of National Significance, she founded a HIV primary care clinic in 2013 within Philadelphia's syringe service program. She was selected as a member of the Mayor's Task Force to Combat the Opioid Epidemic in Philadelphia in 2017 and testified in federal court in 2019 as a fact witness on behalf of Safehouse, Philadelphia's proposed opioid overdose prevention site. She currently provides substance use disorder treatment integrated into HIV primary care at Owen Clinic and is a member of the UCSD Addiction Medicine/Pain Medicine Committee and the UCSD Opioid Use Disorder Task Force. She also serves as the coordinator of the newly mandated substance use disorder rotation at UCSD for all Internal Medicine residents and was recently appointed to the Board of Directors at Stepping Stone San Diego which specializes in substance use treatment in the LGBTQ+ community. GUEST: Carla Marienfeld, MD, DFAPA, FASAM Clinical Professor, University of California, San Diego Bio: Carla Marienfeld, MD, DFAPA, FASAM, Clinical Professor at UC San Diego, Medical Director Substance Treatment and Recovery (STAR) Program, Program Director UC San Diego Addiction Psychiatry Fellowship is board-certified in psychiatry, addiction psychiatry, and addiction medicine. She has authored over four dozen publications and edited four addiction treatment related books. 

Between 2010 and 2022 (the latest year for which data are available), 194,375 New Yorkers were diagnosed with hepatitis C (HCV) and of those, 53% (103,213 individuals) are known to have cleared their infection either through treatment or spontaneously. This statistic is worth celebrating, but also highlights the ongoing need for action – the goal outlined in New York State's Hepatitis C Elimination Plan is to reach 80% by 2030. Furthermore, people who inject drugs are disproportionally affected by HCV – in 2022, 48% of newly reported cases of acute HCV in New York indicated injection drug use as a risk factor. And, when analyzing cases with known risk factors, that figure rose to 81% of newly reported acute cases indicating injection drug use. Providing HCV treatment in opioid treatment program (OTP)s is an innovative and necessary strategy to curb the ongoing epidemic and achieve statewide goals for elimination. This episode features Abigail Hunter, MPH, MSN, FNP-BC, sharing her experience providing HCV treatment at an OTP and recommendations for listeners interested in integrating treatment into clinical services.  Related Content: CEI Training “Hepatitis C and Injection Drug Use” - https://ceitraining.org/courses/1148 VOCAL-NY: https://www.vocal-ny.org/ Respectful, Equitable Access to Comprehensive Healthcare (REACH) Program at Mount Sinai: https://www.mountsinai.org/care/primary-care/upper-east-side/ima/reach New York State Department of Health AIDS Institute guideline for the treatment of chronic hepatitis C virus infection in Adults: https://www.hivguidelines.org/hepatitis-care/hcv-treatment/ Taylor, LE. (2020), Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics. Clinical Liver Disease, 16:12-15. https://doi.org/10.1002/cld.921 Addiction Technology Transfer Center Guide to Integrating HCV Services into Opioid Treatment Programs: https://attcnetwork.org/sites/default/files/2020-07/Guide%20to%20Integrating%20HCV%20Services%20into%20Opioid%20Treatment%20-%20July%2024-1.pdf New York State Hepatitis C Elimination Plan: https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/docs/hepatitis_c_elimination_plan.pdf New York State Hepatitis C Dashboard: https://hcvdashboardny.org/  CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/  

In this episode, Tzu-Hao (Howard) Lee, MD; Tatyana Kushner, MD, MSCE; and patient advocate Andrew Reynolds discuss hepatitis C virus (HCV) care in men who have sex with men and pregnant people, including:HCV disease burden in the United StatesScreening recommendations Strategies to overcome barriers to HCV screeningTreatment recommendations, including simplified treatment guidance and considerations for pregnant peopleStrategies to improve treatment uptakePresenters:Tzu-Hao (Howard) Lee, MDAssistant ProfessorSection of Gastroenterology and Hepatology, Department of MedicineDivision of Abdominal Transplant, Department of SurgeryBaylor College of MedicineHouston, TexasTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Gastroenterology/HepatologyDepartment of Obstetrics & GynecologyWeill Cornell MedicineNew York, New YorkAndrew ReynoldsDirector, Health of People Who Use DrugsSan Francisco AIDS FoundationSan Francisco, CaliforniaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Link to full program:https://bit.ly/4j973TNDownloadable slides: https://bit.ly/4gXuBcu

In this episode, Stacey B. Trooskin, MD, PhD, MPH, Mark S. Sulkowski, MD, FIDSA, FAASLD, and Ronni Marks discuss hepatitis C virus (HCV) screening and treatment, focusing on people who use drugs, and highlight the following topics:Screening recommendationsStrategies to improve HCV screeningHCV testingTreatment goalsStrategies to improve HCV treatment uptakePresenters:Stacey B. Trooskin, MD, PhD, MPHExecutive Medical OfficerMazzoni CenterFaculty, University of PennsylvaniaPerelman School of MedicinePhiladelphia, PennsylvaniaMark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandRonni MarksFounder/Director, The Hepatitis C Mentor and Support Group (HCMSG)Patient AdvocateNew York, New YorkLink to full program:https://bit.ly/4grbwPT

Wirus HCV nie odpuszcza. Wciąż badamy się za mało i przede wszystkim - nie uczymy tego swoich dzieci. Szacuje się, że wirusem HCV, prowadzący do WZW typu C, raka i marskości wątroby zarażone jest 2 procent społeczeństwa - wie o tym mniej niż połowa. 

The insurance landscape for heavy commercial vehicles (HCV) and goods in transit (GRT) is rapidly evolving, driven by trends in risk management and technological advancements. Fleet owners are increasingly adopting strategies such as telematics and surveillance cameras to enhance safety and efficiency. This shift necessitates a more in-depth underwriting process, where insurers assess how well fleet owners manage their vehicles and drivers. Brokers play a vital role, bridging the gap between insurers and clients by educating them on risk mitigation options. As the industry grows, opportunities for brokers and fleet owners to innovate and improve safety are abundant. 

Dive into the fascinating world of virology as we welcome Nobel Prize-winning virologist Dr. Michael Houghton on this episode of Discovery Matters. We explore Dr. Houghton's groundbreaking work in identifying the hepatitis C virus (HCV) and his enduring quest to combat this global health threat. From the monumental discovery of HCV in 1982 to the revolutionary diagnostic tests that nearly eradicated transfusion-related hepatitis C by the mid-1990s, Dr. Houghton provides an engaging and insightful journey through decades of scientific innovation. Show notes Richard D Roberts, Patrick C Kyllonen, ‘Morningness–eveningness and intelligence: early to bed, early to rise will likely make you anything but wise!' Personality and Individual Differences, Volume 27, Issue 6, 1999. https://doi.org/10.1016/S0191-8869(99)00054-9. Taquet, MaximeLone, Nazir et al. ‘Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK.' The Lancet Psychiatry, Volume 11, Issue 9. https://doi.org/10.1016/S2215-0366(24)00214-1

 - Trung tâm Kiểm soát bệnh tật (CDC) TP. Cần Thơ vừa tổ chức tập huấn và điều trị viêm gan C cho phòng khám ARV, methadone và cộng đồng. Hoạt động tập huấn này nằm trong nghiên cứu thí điểm tích hợp xét nghiệm tải lượng HCV (viêm gan C) và HIV vào hệ thống GeneXpert hiện có. Nghiên cứu được triển khai tại Trung tâm Y tế quận Nam Từ Liêm (Hà Nội) và Bệnh viện Đa khoa quận Thốt Nốt (Cần Thơ). Thời gian thí điểm từ tháng 3/2023 đến tháng 12/2024. Chủ đề : cần thơ, hiv --- Support this podcast: https://podcasters.spotify.com/pod/show/vov1tintuc/support

Have you ever had a virus that lingers, or even recurs? There are a group of viruses known as ‘persistent viruses'' that can linger in our bodies for years. Examples include; long covid, herpes, hepatitis (HBV or HCV), epstein-barr virus (EBV), chronic fatigue and many more. Host Amelia Phillips and author Lee Holmes discuss how these viruses impact our health and how a low histamine and low inflammatory approach may help.  In Lee's latest book Natures way to healing: A long covid guide, she shares her own long covid experience, plus latest research, and many low inflammatory, low histamine recipes. Purchase her book here: https://www.booktopia.com.au/nature-s-way-to-healing-lee-holmes/book/9781922786043.html  About the guest: Lee Holmes is a qualified clinical nutritionist, whole-foods chef and author of nine bestselling books including: Supercharged Food: Heal Your Gut, which has been reprinted 12 times. She owns a health food brand and appears regularly in the media.  Follow Lee on Instagram: https://www.instagram.com/leesupercharged/  About the host: Amelia Phillips is a registered exercise scientist and nutritionist with a career spanning 26 years in health. She's a registered exercise scientist, nutritionist and researcher (with a Masters of Human Nutrition). She was the co-founder of health tech company 12WBT which grew from start-up and more recently Inner Vitality, an 8 week online program using biomarkers and personalised health that she runs with an Integrative GP.  Amelia also consults to health companies, presents and appears in the media, most recently on the Ch9 show Do You Want to Live Forever. Amelia had four kids in five years and is dedicated to empowering women to build a life after kids on the foundation of health (mental and physical), connection and purpose.  If you have a question for Amelia, reach out via Insta @_amelia_phillips, email ap@ameliaphillips.com.au  Find out more at www.ameliaphillips.com.au Find out more about Inner Vitality, a new approach to your health: https://innervitality.ameliaphillips.com.au/pages/  CREDITSHost: Amelia Phillips                                                                                                        Guest:  Lee Holmes                                                                                                              Audio Producer: Darren RothMusic: Matt Nicholich                                                                                                      Production Partner: Nova Entertainment Pty Ltd Healthy Her acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures. See omnystudio.com/listener for privacy information  See omnystudio.com/listener for privacy information.

In this special bonus episode, we welcome Principal Deputy Assistant Secretary Richard J. Monocchio from the Office of Public and Indian Housing in the U.S. Department of Housing and Urban Development to discuss the Housing Choice Voucher Program and property manager participation.For more information on participating in the HCV Program and to access property management resources, visit hud.gov. Find knowledge for the dynamic world of real estate management at irem.org.

It's National Recovery Month! In this episode, Neil and Will sit down with Dr. Daniel Moore and Sarah Laurel, two experts on chronic hepatitis C (HCV) and the link to injection drug use.  While not from the region, they speak specifically about the health effects of this in Appalachia.  Leading into National Recovery Month in September, the numbers of this disease are staggering.  Approximately 2.4 million Americans are living with HCV, with cases more than doubling over the past ten years with the opioid epidemic exacerbating the rise. Today, it is estimated that 50% of people who inject drugs are also living with HCV.  Hear Dr. Moore and Sarah speak on the importance of education and outreach as approximately 40% of people living with it are totally unaware they have it.  Take a listen as they advocate for interventions and the possibility of elimination...does that mean there is a cure?  Listen and find out!  You might even hear Neil's jealousy as it pertains to a another brother duo from the "big city."  Also, don't forget about the #AppBiz(s) of the week: Reintegrate Appalachia; and Dirty Girl Coffee! Savage Sisters Recovery - www.savagesisters.org  App News: The "Scruffy Little City" of Knoxville, TN - www.cnn.com/travel/knoxville-tennessee-best-towns-america/index.html  Hydrogen Hub Opening - www.ideastream.org/environment-energy/2024-08-26/appalachian-hydrogen-hub-opens-some-question-if-it-will-bring-clean-energy  Healing Appalachia - https://healingappalachia.org AppBiz: Reintegrate Appalachia - www.reintegrateappalachia.org Dirty Girl Coffee - www.dirtygirlcoffee.com 

rWotD Episode 2669: ViroPharma Welcome to Random Wiki of the Day, your journey through Wikipedia’s vast and varied content, one random article at a time.The random article for Saturday, 24 August 2024 is ViroPharma.ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.The company had strategic relationships with GlaxoSmithKline, Schering-Plough, and Sanofi-Aventis. ViroPharma acquired Lev Pharmaceuticals in a merger in 2008.This recording reflects the Wikipedia text as of 00:01 UTC on Saturday, 24 August 2024.For the full current version of the article, see ViroPharma on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Mastodon at @wikioftheday@masto.ai.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm neural Matthew.

Tim Ulbrich, YFP CEO, talks with the five recipients of the first YFP Gives scholarships. Summary This episode is filled with inspiration as we share the stories of the five winners of the first YFP Gives scholarship. Let this episode be a ray of sunshine amidst some of the cloudy skies plaguing the pharmacy profession. If the future is in the hands of these outstanding students and new practitioners, then the future is bright. In this episode, you'll meet:  Alyssa Falleni, clinical pharmacist who specializes in addiction treatment, HCV, and HIV and is currently working in HIV outpatient care at Hartford Healthcare Momitul Talukdar, who after working in the radiology department at a hospital, discovered her calling as a nuclear pharmacist. Momi currently works at PETNET in Cleveland, OH Perrigrine Garner, a pharmacy student at the University of Toledo with a passion for helping those in need and a dream of owning an independent pharmacy that caters to those with chronic medical conditions and disabilities Ruth Adeyemi, a fourth-year PharmD/MPH Nigerian International student at the University of Florida College of Pharmacy and College of Public Health and Health Professions, with a deep-rooted commitment to improving health outcomes in underserved communities, particularly in her home country, Nigeria. Ai Len Nguyen Phan, a Rutgers Industry Fellow at Roche Genentech in San Francisco, with a desire to work in medical affairs and give back to the pharmacy community through her mentorship to the Rutgers pharmacy students About Today's Guests Alyssa Falleni is a clinical pharmacist who specializes in addiction treatment, HCV, and HIV. After graduating from the University of Rhode Island, Alyssa went on to complete an ambulatory care residency at Hennepin Healthcare in Minneapolis, MN. Following residency, Alyssa completed a two-year VA Advanced Fellowship in Health Professions' Education, Evaluation, and Research (HPEER) at the VA in West Haven, Connecticut. She will be continuing her teaching with the Yale School of Medicine as she begins a new HIV specialty position with Hartford Healthcare. Momi Talukdar, MS, PharmD Candidate 2024 is a graduate of Northeast Ohio Medical University College of Pharmacy. She's an incoming nuclear pharmacist at PETNET in Cleveland, OH. Along with her passion for nuclear pharmacy, she loves teaching nuclear pharmacy as an adjunct faculty at University of Wisconsin LaCrosse. In her spare time, Momi enjoys watching new films and art shows and trying out local coffee shops. Ai Len (Aileen) Nguyen Phan is a second-year Rutgers Pharmaceutical Industry Fellow at Genentech, Inc. - Rare Blood Disorders Medical Science Liaison. She graduated from the University of Maryland, School of Pharmacy with her Pharm.D. and M.S. in Regulatory Sciences in 2023. She supported the US Medical Information & Communication Target Therapies teams during the first year of her fellowship. While Aileen has just recently started her industry career, she continues to give back to the pharmacy community through her mentorship to the Rutgers pharmacy students, such as supporting their scientific research on using artificial intelligence to assess oncology treatments. Perrigrine Garner, a non-traditional student, and mother of three amazing daughters, is currently a P4 at the University of Toledo's College of Pharmacy and Pharmaceutical Sciences. Perrigrine is passionate about advocating for people with disabilities, especially in healthcare, as she is also a person with physical disabilities. Upon graduation, her dream is to help advance inclusivity in her community by opening an independent pharmacy that caters to those with chronic medical conditions and disabilities.  Ruth Adeyemi, a fourth-year PharmD/MPH Nigerian International student at the University of Florida College of Pharmacy and College of Public Health and Health Professions. Her journey in pharmacy is fueled by a deep-rooted commitment to improving health outcomes in underserved communities, particularly in my home country, Nigeria. With this passion, she started The Compassionate Pharmacy Practice Project (TCPPP), a project dedicated to transforming the Nigerian pharmacy practice system. The goal is to ensure that Good Pharmacy Practice (GPP) and Compassionate Care are not just concepts but realities in both urban and rural areas, significantly improving health outcomes in these communities. While Ruth is Nigerian, her commitment to improving health equity in underserved communities extends beyond borders. She is dedicated to her goal of ensuring that all patients, regardless of their neighborhood and built environment, receive the patient-centered, optimal, and compassionate care they deserve. Mentioned on the Show YFP Gives Ruth Adeyemi LinkedIn Alyssa Falleni LinkedIn Perrigrine Garner LinkedIn Momitul Talukdar LinkedIn Ruth Adeyemi Links:  https://sarmlife.com/  Books [Mastering the Art of Blogging for Your Brand] [Mastering the Art of SEO for Brand Growth] [Book Bundle - Discounted Price for purchasing both books] YFP Disclaimer Subscribe to the YFP Newsletter Tim Ulbrich on LinkedIn YFP on Instagram YFP Facebook Group  

HEALTH NEWS   ·         Getting fats from plants vs. animals boosts your life span: Study ·         N-acetylcysteine usage associated with lower risk of liver cancer in HCV patients ·         Algorithm achieves 98% accuracy in disease prediction via tongue color ·         Lack of purpose and personal growth in older age may precede mild cognitive impairment ·         Australia offers lessons for increasing American life expectancy ·         Anti-inflammatory diet could lower your odds for dementia

00:00:00 - Surf's Up: Season 5 Episode 25 On July 20, Clinical Gastroenterology and Hepatology released the paper, Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to non-cirrhotic Advanced Fibrosis. Corresponding author Maru Rinella joins the Surfers to share key points from the recommendations and offer her thoughts on what lay behind them.00:02:26 - Introduction and GroundbreakerThe highlight was Louise's groundbreaker: having become a full Fellow in the Roal College of Physicians.00:06:28 - Introducing the paperRoger starts by discussing the importance of this paper and listing the questions the panel will address during the episode. Maru provides a history of developing the paper. Jörn praises its timeliness. 00:08:59 - Treating the "Right" patients; Using the "Right" testsJörh asks why the authors changed the patient definition from a histological one to at-risk MASH patients confirmed by NITs. Maru said the authors sought to follow the FDA guidance on NITs and patient targets. They considered adding liver enzymes or confirmatory VCTE to the protocol, but demurred because not every clinical could execute such a recommendation. Jörn asks whether the authors considered requiring three metabolic risk factors. Roger notes that this question implies a need to prioritize patients, which is a factor in Europe but not the U.S. This paper takes a more U.S-based perspective, which is to set a threshold for use.  00:14:21 - The Decision Not to Discuss CostThe authors did not address costs because they anticipated steep reductions over time. The panel compares the MASH case to HCV. In HCV, the combination of high drug costs and large number of warehoused patients drove prioritization over time. 00:16:34 - Relative paucity of warehoused MASH patients Maru suggests relatively few MASH patients are warehoused. Louise asks whether many U.S. insurers are controlling access by requiring liver biopsy. Maru reports she has not encountered this personally and  estimates it might affect ~5% of cases so far. 00:19:05 - Rationale for Patient SelectionMaru explains the rationale for an F2 threshold for patient selection: patients with fibrosis >= F2 show a demonstrable decline in long-term survival. The rationale for excluding cirrhosis patients? Resmetirom is not yet proven to help patients with cirrhosis. Jörn notes, the MAESTRO-OUTCOMES trial is running and will generate consequential data on cirrhosis. 00:22:11 - Value of Stabilizing Disease without ImprovementMaru notes that the paper focused strongly on how to stabilize patients because the drug is safe and stabilization has real-world benefits.. She points out that patient advocates strongly recommend this focus. All this led to the paper's recommendation to discontinue only upon progression.  00:25:12 - The importance of incremental learningThe group agrees that these recommendations comprise a base that will be strengthened over time as individual providers gain experience with the drug. 00:30:06 - Wrapping upPanelists touch briefly on the value of loose discontinuation rules, how patients feel about starting therapy, how to handle drug interactions, and how the paper is used in the US vs. other countries. In closing, the group remembers Stephen Harrison's unique contributions one more time.00:37:55 - Question of the WeekWhich of the paper's two striking recommendations -- using multiple NITs to qualify patients and continuing therapy unless and until a patient shows signs of disease progression -- will have greater impact on how physicians treat patients?00:38:44 - Business ReportSummer schedules, value of the business report, the vault discussion.

 - Lãnh đạo các Đảng, các nước chúc mừng Tổng Bí thư, Chủ tịch nước Tô Lâm- Người có đất bị thu hồi được hưởng chính sách giải quyết việc làm và đào tạo nghề hoặc vay vốn lãi suất thấp- Bế mạc Lễ hội Vịnh ánh sáng quốc tế Nha Trang 2024- Thái Lan Malaysia quyết tâm đưa khu vực biên giới 2 nước thành “vùng đất vàng”- Thể thao Đông Nam Á có tấm HCV đầu tiên ở Olympic 2024 sau 1 tuần tranh tài Chủ đề : đào tạo nghề, thu hồi đất --- Support this podcast: https://podcasters.spotify.com/pod/show/vov1thoisu0/support

On today's special episode of Hot Topics and Kidney Health we're sharing audio from a recent webinar hosted by National Kidney Foundation on kidney xenotransplantation. Stay tuned to hear from the experts and learn about the latest updates on animal-to-human transplantation.   Dr. Tatsuo Kawai is a professor of surgery at Harvard Medical School and the A. Benedict Cosimi Chair in Transplant Surgery at Massachusetts General Hospital. He is also director of the Legorreta Center for Clinical Transplantation Tolerance. He was awarded the Martin Research Prize at MGH in 2009 and the New Key Opinion Leader Award by the Transplantation Society in 2010 for this work. In the field of xenotransplantation, he has collaborated extensively with eGenesis over the past five years, achieving over two years of survival for genetically edited kidney xenografts in nonhuman primates, which was published in Nature in 2023. In March 2024, he successfully performed the world first kidney xenotransplantation from the pig with 69 genomic edits in a living patient with end stage renal disease.  Vineeta Kumar MD, FAST, FASN  is the lead nephrologist for the Living Kidney Donor and Incompatible Kidney Transplant programs at the University of Alabama in Birmingham. She is an expert in kidney transplantation, living kidney donation, incompatible kidney transplant, kidney paired donation and cardiovascular outcomes after kidney transplantation. Peter Reese, MD, PhD, is an NIH-funded transplant nephrologist and epidemiologist. His research focuses on: a) developing effective strategies to increase access to solid organ transplantation; b) improving the process of selecting and caring for living kidney donors; c) determining outcomes of health policies on vulnerable populations with renal disease, including the elderly; d) testing strategies to improve important health behaviors such as medication adherence; and e) transplant ethics. He was a recipient of a Presidential Early Career Award for Scientists and Engineers, was elected member of the American Society of Clinical Investigation, and was a Greenwall Faculty Scholar in bioethics. He is a past chair of the Ethics Committee for the United Network for Organ Sharing (UNOS), which oversees organ allocation and transplant regulation in the US, and is an Associate Editor for the American Journal of Kidney Diseases. He co-led the THINKER, USHER, MYTHIC, and SHELTER trials involving transplanting HCV-infected donor organs into uninfected recipients. His work has been generously funded by foundations and the NIH, including a K-24 to support mentoring.   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Responsible for 1.3 million deaths and 2.2 million new infections per year, viral hepatitis is the second leading cause of morbidity and mortality amongst all infectious diseases, just behind tuberculosis.  Hosts Angela Huttner and Oana Sandulescu welcome special guest and leading hepatitis expert, Professor Mojca Matičič, MD, PhD (Ljubljana, Slovenia), to refresh your knowledge on the pathogenesis of hepatitis B & C infections, review the latest direct-acting antiviral (DAA) therapies, map out some countries' successful elimination initiatives, and understand challenges remaining for others. In recognition of World Hepatitis Day this Sunday, 28 July, a day dedicated to raising awareness about viral hepatitis, we are releasing our latest episode a few days early. The World Hepatitis Day theme this year is: it's time for action! The Communicable team urges our listeners to inform themselves and others, and to test, treat, and vaccinate against viral hepatitis.  This episode was peer reviewed by Dr. Liem Luong of CIC Cochin Pasteur, Hôpital Cochin-Port Royal, Assistance Publique-Hôpitaux de Paris, Paris, France. LiteratureWorld Hepatitis Day 2024: It's time for action. Geneva: World Health Organization; 2024. https://www.who.int/campaigns/world-hepatitis-day/2024 Method for global reporting on disease burden and service coverage data for viral hepatitis B and C, 2022. In: Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. doi: 10.2471/B09024. The European Association of the Study of the Liver (EASL). EASL Congress Milan, Italy 5-8 June 2024. https://www.easlcongress.eu/European Centre for Disease Prevention and Control (ECDC). ECDC Evidence brief: Prevention of hepatitis B and C in the EU/EEA. Stockholm: ECDC; 2024.  European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2022. Stockholm: ECDC; 2024.  Burnet Institute and Kirby Institute. Australia's progress towards hepatitis C elimination: annual report 2022. Melbourne: Burnet Institute; 2022. Maticic M, Pirnat Z, Leicht A, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J. 2020 Nov 19;17(1):89. doi: 10.1186/s12954-020-00439-3.

Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company. She elaborates on Meira's cutting-edge approach to genetic medicines, focusing on the development of innovative therapies for non-inherited diseases. Zandy discusses the unique challenges and opportunities that arise in the biotech sector, shedding light on the strategies Meira employs to navigate this complex landscape. Biography: Alexandria Forbes, Ph.D. is the President and CEO of MeiraGTx (NASDAQ: MGTX). MeiraGTx is a vertically integrated gene therapy company with core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. The company is developing innovative gene therapy products to cost effectively treat a range of serious medical disorders, with clinical programs currently in the eye, salivary gland and CNS. Prior to founding MeiraGTx, Dr. Forbes served as Senior Vice President of Commercial Operations at Kadmon Holdings, Inc., a biopharmaceutical company, from September 2013 to April 2015.Before joining the biotech industry, she spent 10 years as a healthcare investor at Sivik Global Partners (Argus Partners) and Meadowvale Partners. At Sivik, Dr. Forbes was responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics public equities and was portfolio manager of the Sivik Global Life Science Fund, a long-biased public markets fund investing in biotechnology companies globally. During her time as a biotechnology investor, Dr. Forbes covered over 300 companies and gained expertise in biotechnology business strategies and clinical drug development as well as a wide range of disease areas. Particular areas of focus included HIV, HCV, diabetes, obesity, autoimmune disorders, cancer, Alzheimer's disease, kidney disease and liver disease. Before entering the hedge fund industry, Dr. Forbes was an academic scientist studying the regulation of stem cell identity and different aspects of embryogeneis. She was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, where her research focused on cytoplasmic determinants and cell signaling pathways involved in the migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to this, Dr. Forbes was a research fellow at Duke University and at the Carnegie Institute at Johns Hopkins University where she studied the role of the hedgehog gene and its signaling pathway in the Drosophila embryo and adult. Dr. Forbes received her Ph.D. in Molecular Genetics from Oxford University, UK and attained a double first degree in Natural Sciences from Cambridge University, UK. Dr. Forbes serves on the Board of Directors of MeiraGTx, and as a Trustee and Director of the Selfridges Group Foundation, the European arm of the Weston Brain Institute, a charity supporting research into neurodegenerative diseases with the aim of speeding the time to the development of disease modifying treatments for these currently intractable diseases, particularly Alzheimer's.

On this episode of the NAA Apartmentcast, the official podcast of the National Apartment Association, we sit down with U.S. Department of Housing and Urban Development (HUD) Principal Deputy Assistant Secretary, Office of Public and Indian Housing Richard Monocchio.  HUD and NAA have announced a unique and important collaboration, which features a seven-stop roadshow in advance of the 50th anniversary of the Housing and Community Development Act and creation of the Section 8 Housing Choice Voucher Program.This collaboration between NAA and HUD gives the rental housing industry a unique opportunity to share feedback and speak directly to HUD officials, as well as gives HUD the chance to hear real-time feedback on the nuance and challenges housing providers face with the HCV program. The tour, which kicked off in Philadelphia at NAA's Apartmentalize, will feature stops in Boston, Charlotte, Cleveland, El Paso, Lansing, Las Cruces and Tampa.Stay tuned to NAAHQ.ORG for ongoing updates on this important partnership. 

Hepatitis C virus (HCV) is a pathogen spread by contact with blood from a person with HCV infection. Prevalence among the US obstetric population rose nearly 10-fold over the past 20 years and approximately 6% of infants born to people with HCV become infected during pregnancy or delivery. The New York State Hepatitis C Elimination Plan outlines over 30 recommendations to eliminate HCV in the state by 2030, including implementation of universal screening for all adults. And in 2023, state legislators approved expanding the existing hepatitis C virus (HCV) testing law to include screening during each pregnancy; changes will go into effect on May 3rd, 2024. This special edition of “Conversations with CEI” describes best practices for screening and identifying hepatitis C and substance use in pregnant persons and linking people to care and treatment. The conversation identifies key steps clinicians can take to support pregnant persons in their care, including ways to operationalize critical health systems for universal hepatitis C screening among pregnant persons. Related Content:  New York State Hepatitis C Screening during Pregnancy, Digital Provider Toolkit: https://ceitraining.org/documents/HCV%20Screening%20for%20Pregnant%20People%20-%20Provider%20Toolkit%20MARCH%202024%20for%20Posting.pdf New York State Department of Health AIDS Institute guideline for treatment of chronic HCV with direct-acting antivirals, Pregnancy and HCV: https://www.hivguidelines.org/hepatitis-care/treatment-with-daa/#tab_4 New York State Department of Health AIDS Institute guideline for substance use disorder treatment in pregnant adults: https://www.suguidelinesnys.org/guideline/substance-use-disorder-treatment-in-pregnant-adults/ National Harm Reduction Coalition “Pregnancy and Substance Use: A Harm Reduction Toolkit” https://harmreduction.org/issues/pregnancy-and-substance-use-a-harm-reduction-toolkit/ Ramsey KS, Cunningham CO, Stancliff S, et al.; Substance Use Guidelines Committee. Substance Use Disorder Treatment in Pregnant Adults [Internet]. Baltimore (MD): Johns Hopkins University; 2021 Jul. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572854/ CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/

Hepatitis C virus (HCV) is a pathogen spread by contact with blood from a person with HCV infection. Prevalence among the US obstetric population rose nearly 10-fold over the past 20 years and approximately 6% of infants born to people with HCV become infected during pregnancy or delivery. The New York State Hepatitis C Elimination Plan outlines over 30 recommendations to eliminate HCV in the state by 2030, including implementation of universal screening for all adults. And in 2023, state legislators approved expanding the existing hepatitis C virus (HCV) testing law to include screening during each pregnancy; changes will go into effect on May 3rd, 2024. This special edition of “Conversations with CEI” describes common barriers people who use substances face when seeking health care services, particularly HCV screening during pregnancy. The conversation also identifies best practices clinicians can implement in practice to provide responsive care for people who use drugs, including pregnant persons. Related Content:  New York State Hepatitis C Screening during Pregnancy, Digital Provider Toolkit: https://ceitraining.org/documents/HCV%20Screening%20for%20Pregnant%20People%20-%20Provider%20Toolkit%20MARCH%202024%20for%20Posting.pdf New York State Department of Health AIDS Institute guideline for treatment of chronic HCV with direct-acting antivirals, Pregnancy and HCV: https://www.hivguidelines.org/hepatitis-care/treatment-with-daa/#tab_4 New York State Department of Health AIDS Institute guideline for substance use disorder treatment in pregnant adults: https://www.hivguidelines.org/substance-use/sud-treatment-pregnancy/ National Harm Reduction Coalition “Pregnancy and Substance Use: A Harm Reduction Toolkit” https://harmreduction.org/issues/pregnancy-and-substance-use-a-harm-reduction-toolkit/ Ramsey KS, Cunningham CO, Stancliff S, et al.; Substance Use Guidelines Committee. Substance Use Disorder Treatment in Pregnant Adults [Internet]. Baltimore (MD): Johns Hopkins University; 2021 Jul. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572854/ CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/

Today I am joined by Dr. Julie Steinbrink, assistant professor of medicine at the Division of Infectious Disease at Duke University School of Medicine. In this episode, we are discussing fungal diagnostics, transcriptional signatures, and also HCV in transplant. 

Hepatitis C virus (HCV) is a pathogen spread by contact with blood from a person with HCV infection. Prevalence among the US obstetric population rose nearly 10-fold over the past 20 years and approximately 6% of infants born to people with HCV become infected during pregnancy or delivery. The New York State Hepatitis C Elimination Plan outlines over 30 recommendations to eliminate HCV in the state by 2030, including implementation of universal screening for all adults. And in 2023, state legislators approved expanding the existing hepatitis C virus (HCV) testing law to include screening during each pregnancy; changes will go into effect on May 3rd, 2024. This special edition of “Conversations with CEI” will provide important information about pregnancy, HCV and substance use from the perspective of a client with lived experience, with a focus on providing affirming services for all pregnant persons and their infants. Related Content:  New York State Hepatitis C Screening during Pregnancy, Digital Provider Toolkit: https://ceitraining.org/documents/HCV%20Screening%20for%20Pregnant%20People%20-%20Provider%20Toolkit%20MARCH%202024%20for%20Posting.pdf New York State Department of Health AIDS Institute guideline for treatment of chronic HCV with direct-acting antivirals, Pregnancy and HCV: https://www.hivguidelines.org/hepatitis-care/treatment-with-daa/#tab_4 New York State Department of Health AIDS Institute guideline for substance use disorder treatment in pregnant adults: https://www.hivguidelines.org/substance-use/sud-treatment-pregnancy/ American Association for The Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) Recommendations for Testing, Managing and Treating Hepatitis C: https://www.hcvguidelines.org/ The American College of Obstetricians and Gynecologists Clinical Practice Guidelines for Viral Hepatitis in Pregnancy: https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2023/09/viral-hepatitis-in-pregnancy US Centers for Disease Control and Prevention (CDC) Recommendations for Hepatitis C Testing among Perinatally Exposed Infants and Children (2023): https://www.cdc.gov/mmwr/volumes/72/rr/rr7204a1.htm?s_cid=rr7204a1_e&ACSTrackingID=USCDC_921-DM116215&ACSTrackingLabel=MMWR%20Recommendations%20and%20Reports%20%E2%80%93%20Vol.%2072%2C%20November%203%2C%202023&deliveryName=USCDC_921-DM116215 Ramsey KS, Cunningham CO, Stancliff S, et al.; Substance Use Guidelines Committee. Substance Use Disorder Treatment in Pregnant Adults [Internet]. Baltimore (MD): Johns Hopkins University; 2021 Jul. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572854/ CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/

For this special episode recorded live at ASAM's Annual Conference, Kelly Ramsey, MD, MPH, MA, FACP, DFASAM, talks about her journey into the field of addiction medicine and how her early experience dispelled myths she previously heard about people who use drugs. She addresses stigma related to addiction, the prevalence of xylazine in the illicit drug supply*, and the need to recognize and treat appropriately polysubstance drug use and overdoses. Dr. Ramsey also discusses her thoughts about the future of addiction medicine and the importance of harm reduction and meeting patients where they are. She shares what she finds enjoyable about attending ASAM's conference and offers words of wisdom to the new generation of addiction medicine providers. Dr. Ramsey is a board-certified internal medicine and addiction medicine physician who has treated substance use disorder since 2004. She worked as medical director of an academic center-based opioid treatment program (OTP) in the South Bronx before working for nearly a decade for a large FQHC in the Hudson Valley where she created and grew a medication for addiction treatment (MAT) program for opioid use disorder (OUD) and alcohol use disorder (AUD) to 10 sites and 1500 patients. More recently, Dr. Ramsey worked as the chief of medical services at the NYS Office of Addiction Services and Supports (OASAS), in a policy, regulatory, and clinical role. Dr. Ramsey currently works as an addiction medicine and harm reduction consultant as well as providing low threshold clinical care and clinical supervision in addiction medicine in three drug user health hubs in New York. She has provided expert advice to the New York State Department of Health (NYSDOH) AIDS Institute and their Office of Drug User Health (ODUH), serving on numerous committees for about 15 years, providing expertise in addiction medicine, harm reduction, HIV care, and HCV care. Dr. Ramsey was the recipient of the New York State Commissioner's Special Recognition Award for contributions to drug user health in NYS in December 2018. She was the Distinguished Contributions to Behavioral Medicine Award Recipient, awarded by the American College of Physicians (ACP) in April 2023. Dr. Ramsey was awarded the Case Western Reserve University School of Medicine Special Medical Alumni Board Award in October 2023. Dr. Ramsey is the immediate past president of the New York Chapter of the American Society of Addiction Medicine (NYSAM) Board of Directors. In addition, she currently serves as Region I Director, representing NYS, on the national American Society of Addiction Medicine (ASAM) Board of Directors. Links: ASAM's Annual Conference information Finding Lifesaving Solutions to a Dangerous Trend American Society of Addiction Medicine   If you or someone you know is struggling with addiction, you are not alone. Treatment is available and recovery is possible. Visit ASAM's Patient Resources page for more information. The information shared in this podcast episode is for educational purposes only and should not be taken as medical advice. The views expressed in this podcast may not be those of the host or the management.   *The comments in the discussion alluding to 90% of syringes containing xylazine refer to the findings of the following study: The Emerging of Xylazine as a New Drug of Abuse and its Health Consequences among Drug Users in Puerto Rico - PMC (nih.gov).

This episode is a follow-up to Season 4, Episode 5, where we met Tim Jobson. His company, Predictive Health Intelligence (PHI), takes a unique approach to identifying and monitoring MASLD patients using basic EHR data and analytics. This session explores PHI's work over the past years and considers implications for several liver-related health challenges. 00:00:00 - Surf's Up: Season 5 Episode 10Opening comments from the panel, including brief quotes taken directly from the episode. 00:02:04 - Introduction and GroundbreakerEach panelist shares one piece of good news from the previous week.00:07:02 - New projects from TimTim discusses the three major activities that PHI has undertaken since our last visit.00:12:46 - Sequential testingRoger Green asks Tim to state one key lesson he would like to share with a global audience. Tim speaks of the value of sequential testing and the value of collecting data that will support this effort. 00:15:33 - Data governance and privacyLouise Campbell asks Tim about privacy issues and GDPR status for these types of basic health information. Tim states that the number of cases where patients have exhibited concerns when they learn the data is helping them get/stay healthier is virtually nil.00:22:31 - Most and least helpful data itemsTim states that "factual data" (e.g., lab tests) are more valuable than "coded data" reflecting a treater's point of view. 00:25:21 - Thoughts on patient gender and age In response to Louise's questions, Tim shares that his group creates separate analyses by gender, strongly prefers creating risk thresholds to "measures of normality and abnormality," and already is seeing a trend of patients needing MASLD care at younger ages. 00:30:23 - Differences between MASLD and HCVTim discusses some differences in the challenge of bringing in-need HCV patients into the healthcare system compared to in-need MASH patients. HCV patients tend to live at lower socio-economic status, and some who lead high-risk lives may be homeless. MASH patients are more likely simply to lack knowledge and more likely to come to a physician visit once identified. 00:38:38 - Specific challenges in the USIn response to Roger's questions, Tim identifies two differences in the US today: greater clinician motivation due to Rezdiffra coming to market and a greater need for an inexpensive way to target the right patients and then track whether the drug appears to be working.00:41:49 - Keeping data import simpleTim comments that these kinds of activities are challenging enough when data sets and needs are fit to goal and fairly simple, let alone if researchers or policymakers inflate the dataset unnecessarily. This is particularly important because the system can probably locate so many untreated patients using simple data. 00:47:18 - Seeking high-value patients more effectively and final questionLouise and Tim consider what might be the "sweet spot" when patients are ill enough to appreciate that they need treatment but still hardy enough that therapy has time to work. From there, Roger asks a final question about how all stakeholders can contribute to the goal of aggregating large-scale basic sequential data.00:52:52 - Question of the WeekThe question asks what help listeners' organizations or others like them can offer in providing data or otherwise helping enrich data sources for assessing the value of repeat measures. 00:53:37 - Business ReportThis week's news on audience metrics, post-Rezdiffra episode ideas and this week's Vault conversation.

Vincent travels to the University of Heidelberg to speak with Volker Lohmann about his career and the research of his laboratory on hepatitis C virus, hepatitis A virus, and norovirus. Host: Vincent Racaniello Guests: Volker Lohmann Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Become a member of ASV (asv.org) The New City by Dickson Despommier HCV human challenge studies (Lancet Gastro Hepatol) Comparison of HCV and HAV infections (J Hepatol) HCV cell culture systems (J Med Chem) Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Episode 164: More Than Just A HeadacheDr. Song presents a case of a subacute headache that required an extensive workup and multiple visits to the hospital and clinic to get a diagnosis. Dr. Arreaza added comments about common causes of subacute headaches.    Written by Zheng (David) Song, MD. Editing and comments by Hector Arreaza, MD.  You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Introduction to the episode: We are happy to announce the class of 2027 of the Rio Bravo / Clinica Sierra Vista Family Medicine Residency Program. Our new group will be (in alphabetical order): Ahamed El Azzih Mohamad, Basiru Omisore, Kenechukwu Nweke, Mariano Rubio, Nariman Almnini, Patrick De Luna, Sheila Toro, and Syed Hasan. We welcome all of you. We hope you can enjoy 3 enriching and fulfilling years. During this episode, you will hear a conversation between Dr. Arreaza and Dr. Song. Some elements of the case have been modified or omitted to protect the patient's confidentiality. 1. Introduction to the case: Headache. A 40-year-old male with no significant PMH presents to the ED in a local hospital due to over a month history of headaches. Per the patient, headaches usually start from the bilateral temporal side as a tingling sensation, and it goes to the frontal part of the head and then moves up to the top of the head. 8 out of 10 severities were the worst. Pt reports sometimes hypersensitivity to outdoor sunlight but not indoor light. OTC ibuprofen was helpful for the headache, but the headache always came back after a few hours. The patient states that if he gets up too quickly, he feels slightly dizzy sometimes, but it is only for a short period of time. There was only one episode of double vision lasting a few seconds about 2 weeks ago but otherwise, the patient denies any other neurological symptom. He does not know the cause of the headache and denies any similar history of headaches in the past. The patient denies any vomiting, chest pain, shortness of breath, cough, abdominal pain, or joint pain. The patient further denies any recent traveling or sick contact. He does not take any chronic medication. The patient denies any previous surgical history. He does not smoke, drink, or use illicit drugs. What are your differential diagnoses at this moment? Primary care: Tension headache, migraines, chronic sinusitis, and more.2. Continuation of the case: Fever and immigrant.Upon further inquiries, the patient endorses frequent “low-grade fever” but he did not check his temperature. He denies any significant fatigue, night sweats, or weight loss. He migrated from Bolivia to the U.S. 12 years ago and has been working as a farm worker in California for the past 10 years. He is married. His wife and daughter are at home in Bolivia. He is currently living with friends. He is not sexually active at this moment and denies having any sexual partners. Differential diagnoses at this moment?  Tension headache, migraine, infections, autoimmune disease, neurocysticercosis. 3. Continuation of the case: Antibiotics and eosinophilia. As we kept asking for more information, the patient remembered he visited a clinic about four months ago for a dry cough and was told he had bronchitis and was given antibiotics and the cough got better after that. He went to another local hospital ED one month after that because the cough came back, now with occasional phlegm and at that time he also noticed two “bumps” on his face but nothing significant. After a CXR at the ED, the patient was diagnosed with community-acquired pneumonia and sent home with cough medication and another course of antibiotics. His cough improved after the second round of antibiotics. We later found on the medical record that the CXR showed “mild coarse perihilar interstitial infiltrates of unknown acuity”. His blood works at the ED showed WBC 15.2, with lymphocyte 21.2%, monocyte 10.1%, neutrophil 61.7%, eosinophil 5.9% (normally 1-4%), normal kidney, liver functions, and electrolytes, and prescribed with benzonatate 100mg TID and doxycycline 100mg bid for 10 days. He went to the same ED one month before he saw us for headache and fever (we reviewed his EMR, and temp was 99.8F at the ED). After normal CBC, CMP and chest x-ray. The patient was diagnosed with a viral illness and discharged home with ibuprofen 400mg q8h.Due to the ongoing symptoms of headache and fever, the patient went back to the same clinic he went to four months ago for a dry cough and requested a complete physical and blood work. The patient was told he had a viral condition and was sent home with oseltamivir (Tamiflu®) for five days. However, the provider did order some blood work for him. Differential diagnoses at this moment?  Patients with subacute meningitis typically have an unrelenting headache, stiff neck, low-grade fever, and lethargy for days to several weeks before they present for evaluation. Cranial nerve abnormalities and night sweats may be present. Common causative organisms include M. tuberculosis, C. neoformans, H. capsulatum, C. immitis, and T. pallidum. At his physical exam visit, the patient actually asked the provider specifically to check him for coccidiomycosis because of his job as a farm worker and he heard from his friends that the infection rate is pretty high in the Central Valley of California. His serum cocci serology panel showed positive IGG and IGM with CF titer of 1:128. His HIV, syphilis, HCV, HBV are all negative. The patient was told by that clinic to come to ED due to his history of headache, fever, and very high serum coccidiomycosis titer.  The senior and resident intern were on the night shift that night and we were contacted by the ED provider at around 9:30 pm for this patient. When reviewing his ED record, his vitals were totally normal at the ED, the preliminary ED non-contrast head CT showed no acute intracranial abnormality. A lumbar puncture was performed by the ED provider, which showed WBCs (505 - 71%N, 20%L, 7%M), RBC (1), glucose (19), and protein (200). CSF: High Leukocytes, low glucose, and high protein.On the physical exam, the patient was pleasant and cooperative, he was A&O x 4, he had a normal examination except for two brown healing small nodules on his forehead and left cheek and slight neck stiffness. At that point, we knew the patient most likely had fungal meningitis by cocci except for the predominant WBC in his CSF fluid was neutrophil not the more typical picture of lymphocyte dominant. And because of his very benign presentation and subacute history, we were not 100% sure if we had a strong reason to admit this patient. We thought this patient could be managed as an outpatient with oral fluconazole and referred to infectious disease and neurology. 4. Continuation of case: Admission to the hospital.Looking back, one thing that was overlooked while checking this patient in the ED was the LP opening pressure. Later, the open pressure was reported as 340mm H2O (very high). The good thing was, after speaking to the ED attending and our attending, the patient was admitted to the hospital and started on oral fluconazole.  Three hours after the admission, a rapid response was called on him. While the floor nurses were doing their check-in physical examination, the patient had a 5-minute episode of seizure-like activity which included bilateral tonic arm/hand movements, eye deviation to the left, LOC unresponsive to sternal rub, and the patient desaturated to 77%. He eventually regained consciousness after the seizure and pulse oximetry increased to 100% on room air. The patient was started on Keppra and seen by a neurologist the following day. His 12-hour EEG was normal, but his head MRI showed “diffuse thickening and nodularity of the basal meninges are seen demonstrating enhancement, suggesting chronic meningitis, possibly related to cocci. Other etiologies including sarcoidosis and TB meningitis and/or infiltration by metastatic process/lymphoma are not excluded. The ventricles are slightly prominent in size”. MRI of the cervical, thoracic, and lumbar spines also showed extensive diffuse leptomeningeal thickening, extensive meningitis, and nodular dural thickening. Also, his chest x-ray showed “some heterogeneity and remodeling of the distal half of the left clavicle. Metabolic bone disease, infectious etiology and/old trauma considered”. This could also be due to disseminated cocci infection. The infectious disease doctor saw this patient and recommended continuing with fluconazole, serial LPs until opening pressure is less than 250 mmH2O and neurosurgery consultation for possible VP shunt placement. The neurologist recommended the patient continue with Keppra indefinitely in the context of structural brain damage secondary to cocci meningitis.Take home points: Suspect cocci meningitis in patients with subacute headache associated with respiratory symptoms, new skin lesions, photophobia, neck stiffness, nausea, vomiting, eosinophilia, erythema nodosum (painful nodules on the anterior aspect of legs). Other symptoms to look for include arthralgias, particularly of the ankles, knees, and wrists.____________________Brief summary of coccidiomycosis. Etiology Coccidioidomycosis, commonly known as Valley fever, is caused by dimorphic soil-dwelling fungi of the genus Coccidioides (C. immitis and C. posadasii). They are indistinguishable in clinical presentation and routine laboratory test results.1, 2, 3, 5Epidemiology In the United States, endemic areas include the southern portion of the San Joaquin Valley of California and the south-central region of Arizona. However, infection may be acquired in other areas of the southwestern United States, including the southern coastal counties in California, southern Nevada, southwestern Utah, southern New Mexico, and western Texas (including the Rio Grande Valley). There are also cases in eastern Washington state and in northeastern Utah. Outside the United States, coccidioidomycosis is endemic to northern Mexico as well as to localized regions of Central and South America.1, 2Overall, the incidence within the United States increased substantially over the 1998-2019, most of that increase occurred in south-central Arizona and in the southern San Joaquin Valley of California. From 1998 to2019, reported cases in California increased from 719 to 9004.1, 6The risk of infection is increased by direct exposure to soil harboring Coccidioides. Past outbreaks have occurred in military trainees, archaeologists, construction or agricultural workers, people exposed to earthquakes or dust storms. However, in endemic areas, many cases of Coccidioides infection occur without obvious soil or dust exposure and are not associated with outbreaks. Change in population, climate change, urbanization and construction activities, and increased awareness and reporting, are possible contributing factors.1, 2, 5 Pathology In the soil, Coccidioides organisms exist as filamentous molds. Small structures called arthroconidia from the hyphae may become airborne for extended periods. Arthroconidia are usually 3-5 μm—small enough to evade bronchial tree mucosal mechanical defenses and reach deep into the lungs.1, 3Once inhaled by a susceptible host into the lung, the arthroconidia develop into spherules (theparasitic existence in a host), which are unique to Coccidioides. Endospores from ruptured spherules can themselves develop into spherules, thus propagating infection locally.1, 3, 5Although rare cases of solid organ donor-derived or fomite transmitted infections have been reported, coccidioidomycosis does not occur in person-to-person or zoonotic contagion, and transplacental infection in humans has never been documented.2, 5Cellular immunity plays a crucial role in the host's control of coccidioidomycosis. Among individuals with decreased cellular immunity, Coccidioides may spread locally or hematogenously after an initial symptomatic or asymptomatic pulmonary infection to extrathoracic organs.1, 3, 7Clinical manifestationThe majority of infected individuals (about 60%) are completely asymptomatic. Symptomatic persons (40% of cases) have symptoms that are related principally to pulmonary infection, including cough, dyspnea, and pleuritic chest pain. Some patients may also experience fever, headache (common finding in early-stage infection and does not represent meningitis), fatigue, night sweats, rash, myalgia.1, 2, 3, 5In most patients, primary pulmonary coccidioidomycosis usually resolves in weeks without sequelae and lifelong immunity to reinfection. However, some patients may develop chronic pulmonary complications, such as nodules or pulmonary cavities, or chronic fibrocavitary pneumonia. Some individuals with intense environmental exposure or profoundly suppressed cellular immunity (e.g., in patients with AIDS) may develop a primary pneumonia with diffuse reticulonodular pulmonary process in association with dyspnea and fever.1, 3, 5Fewer than 1% of infected individuals develop extrathoracic disseminated coccidioidal infection. Common sites for dissemination include joints and bones, skin and soft tissues, and meninges. One site or multiple anatomic foci may be affected. 1, 2, 3, 7It is estimated that coccidioidal meningitis, the most lethal complication of coccidioidomycosis, affects only 0.1% of all exposed individuals. Patients with coccidioidal meningitis usually present with a persistent headache (rather than a self-limited headache in some patients with primary pulmonary infection), with nausea and vomiting, and sometimes vision change. Some may also develop altered mental status and confusion. Meningismus such as nuchal rigidity, if present, is not severe.Hydrocephalus and cerebral infarction may develop in some cases. Papilledema is more commonly observed in pediatric patients.1, 3, 4, 5, 7When meningitis develops, most patients may not have any respiratory symptoms nor radiographic manifestation of pulmonary infection. However, a large number of these individuals also present with other extrathoracic lesions.7DiagnosisAlthough early diagnosis carries obvious benefits for patients and the health care systems as a whole (e.g., decreases patient anxiety, reduces the cost of expensive and invasive tests, removes the temptation for empirical antibacterial or antiviral treatments, and allows for early detection of complications), considerable diagnostic delays up to several weeks to months are common in both endemic areas and non-endemic areas.3, 7 Most symptomatic persons with coccidioidal infection present with primarily pulmonary symptoms and are often misdiagnosed as community-acquired bacterial pneumonia and treated with antibiotics. In endemic areas like south-central Arizona, previous studies found up to 29% of community-acquired pneumonia is caused by coccidioidomycosis. Healthcare providers thus should maintain a high clinical suspicion for coccidioidomycosis when evaluating persons with pneumonia who live in or have traveled to endemic areas recently. Elevated peripheral-blood eosinophilia of over 5%, hilar or mediastinal adenopathy on chest radiography, marked fatigue, and failure to improve with antibiotic therapy should prompt suspicion and testing for infection with coccidioidomycosis in endemic areas.1, 3, 5Serological testing plays an important role in establishing a diagnosis of coccidioidomycosis. Enzyme immunoassay (EIA) to detect IgM and IgG antibodies is highly sensitive and therefore commonly used as the screening tool. Immunodiffusion is more specific but less sensitive than enzyme immunoassay. It is used to confirm the diagnosis of positive EIA test results. Complement fixing (CF) test, which indirectly detects the presence of coccidioidal antibodies by testing the consumption of serum complement, are expressed as titers. Serial measurements of titers are of not only diagnostic but also prognostic value.1, 2, 3, 5Other methods, including culture, microscopic, or polymerase chain reaction (PCR) exam on tissue or respiratory specimens, are limited by their availability, sample obtaining and handling, or lack of sufficient evaluation.1, 2, 3, 5Cerebrospinal fluid (CSF) examination in coccidioidal meningitis usually demonstrates lymphocyte dominated elevation of leukocytes, although polymorphonuclear leukocyte dominance can also be seen in the early stage of the infection. Profound hypoglycorrhachia and elevated protein levels in CSF examination are also very common in coccidioidal meningitis.1, 7Although isolating Coccidioides from CSF or other CNS specimens are diagnostic for coccidioidal meningitis, in practice, diagnoses are often made based on the combination of clinical presentation, CSF examination that suggesting fungal infection, and positive Coccidioides antibodies found in CSF.7Imaging, especially enhanced magnetic resonance imaging (MRI), can help in diagnosing coccidioidal meningitis. Basilar leptomeningeal enhancement is a more common finding even though hydrocephalus, cerebral infarction, and vertebral artery aneurysm can also be seen.7TreatmentMost patients with focal primary pulmonary coccidioidomycosis do not require antifungal therapy. According to 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline, antifungal therapy should be considered in patients with concurrent immunosuppression that adversely affect cellular immunity (e.g., organ transplant patients, AIDS in HIV-infected patients, and patients receiving anti–tumor necrosis factor therapy) and those with significantly debilitating illness, extensive pulmonary involvement, with concurrent diabetes, pregnant women, or who are otherwise frail because of age or comorbidities. Some experts would also include African or Filipino ancestry as indications for treatment. Conversely, humoral immunity comprise splenectomy, hypocomplementemia, or neutrophil dysfunction syndromes are not major risk factors for this disease.1, 2, 3, 4, 5Triazole antifungals (fluconazole or itraconazole) are currently considered as the first-line medications used to treat most cases of coccidioidomycosis. Amphotericin B is reserved for only the most severe cases of dissemination and patients with coccidioidal meningitis in whom triazole antifungal therapy has failed. It is also the choice of therapy for coccidioidomycosis in pregnant women during the first trimester because of the possible teratogenic effect of high-dose triazole therapy during this period of time.1, 3, 4, 5Treating coccidioidal meningitis (CM) poses a special challenge because untreated meningitis is nearly always fatal. Lifelong therapy is recommended for CM because the majority 80% patients with CM experience relapse when therapy is stopped despite initial response to antifungal treatment. Shunting of CSF is required in cases of meningitis complicated by hydrocephalus.1, 3, 4, 5, 7Prevention Avoidance of direct contact with contaminated soil in endemic areas (e.g., respirator use by construction workers) may reduce disease risk, although clear evidence of its benefit is lacking.1, 5Some special population groups may benefit from prophylactic use of antifungals, such as those about to undergo allogeneic solid-organ transplantation or patients with a history of active coccidioidomycosis or a positive coccidioidal serology in whom therapy with tumor necrosis factor α antagonists is being initiated. The administration of prophylactic antifungals is not recommended for HIV-1-infected patients even if they live in an endemic region.1, 5Conclusion: Now we conclude episode number 164, “More than just a headache.” Dr. Song explained that a headache with an indolent course, accompanied by subacute respiratory symptoms, nausea, vomiting, photophobia, neck stiffness, and skin lesions can be secondary to Valley Fever. The Central Valley of California, as well as other areas with dry climate, are endemic and we need to keep this disease in our differential diagnosis.This week we thank Hector Arreaza and Zheng (David) Song. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Roos KL, Tyler KL. Acute Meningitis. McGraw Hill Medical. Published 2023. Accessed August 18, 2023. https://accessmedicine.mhmedical.com/content.aspx?bookid=2129§ionid=192020493Information for Healthcare Professionals. Published 2023. Accessed August 18, 2023. https://www.cdc.gov/fungal/diseases/coccidioidomycosis/health-professionals.html#printValley Fever (Coccidioidomycosis) a Training Manual for Primary Care Professionals. Accessed August 18, 2023. https://vfce.arizona.edu/sites/default/files/valleyfever_training_manual_2019_mar_final-references_different_colors.pdfAmpel NM. Coccidioidomycosis. Idsociety.org. Published July 27, 2016. Accessed August 18, 2023. https://www.idsociety.org/practice-guideline/coccidioidomycosis/Herrick KR, Trondle ME, Febles TT. Coccidioidomycosis (Valley Fever) in Primary Care. American Family Physician. 2020;101(4):221-228. Accessed August 18, 2023. https://www.aafp.org/pubs/afp/issues/2020/0215/p221.htmlValley Fever Statistics. Published 2023. Accessed August 18, 2023. https://www.cdc.gov/fungal/diseases/coccidioidomycosis/statistics.htmlUpToDate. Uptodate.com. Published 2023. Accessed August 18, 2023. https://www.uptodate.com/contents/coccidioidal-meningitis?search=7%20Coccidioidal%20meningitis&source=search_result&selectedTitle=1~10&usage_type=default&display_rank=1Royalty-free music used for this episode: Tropicality by Gushito, downloaded on July 20, 2023, from  https://www.videvo.net/

TWiV reveals how viruses participate in the organomineralization of travertines, and how neutralizing antibodies evolve to exploit vulnerable sites in the hepatitis C virus envelope glycoprotein E2 and mediate clearance of infection. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Become a member of ASV (asv.org) Research assistant position in Rosenfeld Lab CBER/FDA (pdf) The New City by Dickson Despommier Global dengue cases rise markedly (WHO) Measles outbreak in Philadelphia (Phil Health Dept) Viruses and organomineralization of travertine (Sci Rep) Neutralizing antibodies and clearance of HCV infection (Immunity) Letters read on TWiV 1079 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Global climate highlights 2023 and 7 new songs you should hear Brianne – Stuff you should know episodes: METI and SETI Kathy – Oppenheimer “Science, Mission, Legacy” documentaries from Los Alamos Lab One Two Three and Los Alamos National Laboratory Summer 2023 National Security Science: The Oppenheimer Issue Rich – The Wager: A Tale of Shipwreck, Mutiny and Murder by David Grann Alan – Less is Morse, an educational game Vincent – Citing Misinformation, Florida Health Official Calls for Halt to Covid Vaccines Listener Picks Sonrisa – Microorganisms in Perspective Anonymous – Wow! Human Cells Vibrate With Resonant Frequency and It's Technically Audible Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

What is a Syndemic?  Lee Storrow, Senior Director of External Affairs at the Community Education Group  joined RHV to discuss the confluence of HIV, HCV, and the opioid crisis and what is being done to address it. If you want to be part of the conversation about rural health, join Lee, myself, and others at the Appalachian Syndemic Summit in May. This episode was sponsored by the Virginia State Office of Rural Health.  

In this episode John, Paul and Will discuss the amazing development in the treatment of the Hepatitis C virus (HCV). This is a deep dive into HCV. From the interferon days through to the amazing discovery of Direct Acting Antiviral (DAAs) that can cure almost 100% of people from HCV making HCV the first curable chronic viral infection. With over 58 million people estimated to still have HCV, there is plenty of work to be done.

In episode 32 we discuss an article about trazodone for sleep in people with opioid use disorder on buprenorphine. Piyush Goyal, Dheeraj Kattula, Ravindra Rao, Roshan Bhad, Ashwani Kumar Mishra, Anju Dhawan. Trazodone for sleep disturbance in opioid dependent patients maintained on buprenorphine: A double blind, placebo-controlled trial. Drug and Alcohol Dependence. Volume 250. 2023. 110891. ISSN 0376-8716.  We also discuss the decriminalization of psychedelics and treating HCV in primary care. From the LA Times: California moves to decriminalize use of magic mushrooms and other natural psychedelics   From the AASLD/ISDA: Recommendations for Testing, Managing, and Treating Hepatitis C ---------- This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, please visit MI CARES. ---------- Episode 32 Credits: Original theme music: composed and performed by Benjamin Kennedy Audio production: Erin McCue Executive Producer: Dr. Patrick Beeman A podcast from Ars Longa Media ---------- This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.  The best part of any journal club is the conversation. Send us your comments on Twitter, Facebook, YouTube, Spotify, email, or join our Facebook group. Email: addictionmedicinejournalclub@gmail.com  Twitter/X: @AddictionMedJC  Facebook: @AddictionMedJC Facebook Group: Addiction Medicine Journal Club YouTube: addictionmedicinejournalclub Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

In this podcast episode, hosts Erica Austin and Ryan Buck welcome two guests, Sarah Hughes and Nicole Johnson, to discuss NMCAA's Homeless prevention program and their upcoming fundraiser. Sarah Hughes is the director of homeless prevention programs at NMCAA, and Nicole Johnson is the homeless prevention program coordinator and HCV (Housing Choice Voucher) and ESG (Emergency Solution Grant) lead. They talk about the importance of addressing homelessness, working with community coalitions, including the Michigan Balance of State Continuum of Care and the Northwest Coalition to End Homelessness, and the significance of including people with lived experience in their programs. Sarah and Nicole also explain the HCV program, which provides housing assistance based on income, the ESG program for short-term rental assistance and eviction prevention, and the unique features of each program. The discussion highlights the challenges of managing waitlists for these programs and the need to prioritize those in the greatest need.

America Out Loud PULSE with Dr. Harvey Risch – Dr. Steven Kritz, with a healthcare legacy spanning 50 years, joins me in a candid conversation. We delve deep into his vast experience, from direct patient care in rural settings to pioneering roles in clinical research on Substance Use, HIV, and HCV. As the current IRB Chair, he voices concerns about the sidelining of medical ethics during the COVID-19 pandemic. Discover how core...

America Out Loud PULSE with Dr. Harvey Risch – Dr. Steven Kritz, with a healthcare legacy spanning 50 years, joins me in a candid conversation. We delve deep into his vast experience, from direct patient care in rural settings to pioneering roles in clinical research on Substance Use, HIV, and HCV. As the current IRB Chair, he voices concerns about the sidelining of medical ethics during the COVID-19 pandemic. Discover how core...

This week, Marianna sits down with two clinicians from the National Clinician Consultation Center (NCCC) - Astha Kanani, MD and Cristina Gruta, PharmD to talk about hepatitis c treatment and adherence when it comes to people with HIV.  --Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=UHL5555)-- Resources mentioned in this episode: https://www.hepatitisc.uw.edu/https://www.hcvguidelines.org/https://www.hep-druginteractions.org/checker https://www.cdc.gov/mmwr/volumes/71/wr/mm7132e1.htmFabbiani M, Lombardi A, Colaneri M, et al. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. J Viral Hepat. 2021;28(3):558-568. Cunningham EB, Amin J, Feld JJ, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study. Int J Drug Policy. 2018;62:14-23.Kattakuzhy S, Mathur P, Gross C, et al. High SVR in PWID with HCV despite imperfect medication adherence: data from the anchor study. Hep

Apply to be a Family Homelessness Coalition fellow! Learn more and apply here: https://www.fhcnyc.org/app/uploads/2023/09/2023-FHC-Housing-Policy-Fellowship-Job-Description-7-26-23.pdf Check out the Portraits of Hope Documentary https://www.fhcnyc.org/portraits-of-hope/ Email or DM us to share your story: ⁠NYCHearOurVoices@gmail.com ⁠ Hear Our Voices on ⁠Twitter⁠, ⁠Instagram⁠, ⁠Facebook⁠, ⁠TikTok⁠ account links can be found on ⁠Linktr.ee/nyc_hov⁠ Learn about the facts on family homelessness in NYC https://www.fhcnyc.org/the-facts/ Fact Sheet Resources NYC311 https://portal.311.nyc.gov/   DHS' Prevention Assistance and Temporary Housing (PATH) intake center - apply for shelter  https://www.nyc.gov/site/dhs/shelter/families/families-with-children-applying.page Brochurehttps://www.nyc.gov/assets/dhs/downloads/pdf/path-brochure.pdf   HRA Guide for Housing Instability https://www.nyc.gov/assets/hra/downloads/pdf/BK-9-SOI-NewGuideForRenters.pdf    FAQ for Source of Income Discriminationhttps://www.nyc.gov/assets/cchr/downloads/pdf/materials/FairHouse_FAQs-Tenant-English.pdf   Unlock NYC (support for discrimination) https://weunlock.nyc/   Housing Vouchers Section 8 also known as Housing Choice Voucher (HCV) program https://www.nyc.gov/site/nycha/section-8/about-section-8.page   CityFHEPS https://www.nyc.gov/site/hra/help/cityfheps.page   FHEPS https://www.nyc.gov/site/hra/help/fheps.page   Special One-Time Assistance (SOTA)https://www.nyc.gov/site/hra/help/sota.page   Domestic Violence Family Justice Centers - Provides free services and confidential services by phone and in person for victims and survivors of domestic and gender-based violence.  https://www1.nyc.gov/site/ocdv/programs/family-justice-centers.page (includes locations and phone numbers)  24-hour Domestic Violence Hotline: 800-621-HOPE (4673) ⁠HRA Domestic and Gender-Based Violence Support⁠ - https://www1.nyc.gov/site/hra/help/domestic-violence-support.page ⁠NYC HOPE Resource Guide⁠ to help you or loved one experiencing domestic or gender-based violence - https://www1.nyc.gov/nychope/site/page/home ⁠Safe Horizon⁠ Victim assistance organization operating a network of programs across New York City communities. They assist survivors of all forms of violence. ⁠https://safehorizon.org⁠ Crime Victims Hotline: 1-866-689-HELP SafeChat offer information, advocacy and support: ⁠https://www.safehorizon.org/safechat/⁠ Other resources: ⁠https://www.safehorizon.org/am-i-being-abused/⁠ 24-hour Hotlines: Safe Horizon's 3 Hotlines: DV - 1-800-621-HOPE Rape and Sexual Assault - 212-227-3000 Crime Victims - 1-866-689-HELP NYC Anti-Violence Project (AVP) (specialize in working with LGBTQ+ survivors) - 212-714-1141 Violence Intervention Project (specialize in working with Latinx survivors) - 1-800-664-5880 New Destiny Housing⁠  ⁠https://newdestinyhousing.org/⁠   646-472-0262 ⁠New Destiny Housing Resource Center⁠ - ⁠https://newdestinyhousing.org/housing-help/⁠    Womankind (specialize in working with Asian survivors) - 1-888-888-7702 ⁠Resources & Services for Orders of Protection⁠ ⁠WomensLaw Legal Information on Restraining Orders⁠ Talk It Out Mental Health Counseling PLLC Talkitoutcounselingservices@gmail.com Check out other resources: ⁠bit.ly/40pB4p8⁠

Co-hosts Louise Campbell and Roger Green are joined by friend of the podcast, Naim Alkhouri, and new guest, Professor James O'Beirne, to discuss liver disease in Australia and developing improved models for patient identification and risk stratification.James , a Consultant Hepatologist at the Sunshine Coast University Hospital, shares his professional background and introduces events which lead to the LOCATE-NAFLD study. After Australia became the first country to allow access to direct-acting antiviral agents for HCV in 2016, there was the strong need to determine which patients were cirrhotic. With relatively unprepared primary care providers, specialist and hospital care were inundated with referrals. In response, James contributed to the inception of a mobile FibroScan program to deliver scans, assessments and treatment recommendations to community health clinics and GP practices. The program was very successful and it was decided that data should be published followed by an economic analysis to demonstrate how this was an effective model of democratizing access to risk stratification. As it was later sought to be applied to different disease areas, the LOCATE-NAFLD project was born. James outlines the parameters which can be read in a succinct overview here: The LOCATE-NAFLD study is a 1:1 parallel randomized trial to compare two alternative models of care for NAFLD (usual care versus LOCATE-NAFLD).Usual care groupPatients will attend a specialist hepatology clinic for their care.LOCATE-NAFLD groupPatients will be assessed by a specialist study nurse in the primary care setting, such as local general practice clinic.The specialist nurse will assess patients using mobile transient elastography, using a FibroScan machine.Scan results will be reviewed by the specialist nurse and hepatologistPatients with low levels of liver scarring will be referred back to their GP for carePatients with high levels of liver scarring will be followed up in secondary care hepatology clinicsQuality of life will be assessed for all patients at baseline and at 12-month follow-up via a questionnaire. The study will analyse intervention costs, hospital outpatient clinic utilization, hospital admissions, hospital costs and patient death data.From here the conversation opens to comments from the other panelists and Naim commends that this effort is being studied in a randomized trial and goes on to ask questions around protocol. Louise discusses the impact conducting FibroScan has on mediating patient behavior and the potential reach this sort of model has as she considers empowering the likes of dieticians and other skilled practitioners. Roger introduces ideas around extrapolating these insights for use in countries outside of Australia and goes on to discuss clinical care pathways and what motivating frontline treaters looks like both in the absence and presence of approved medications. Naim shares his experiences venturing into Arizona with mobile FibroScan consultations, mostly focused on patients with type 2 diabetes, obesity and other risk factors. The second half of the conversation touches more on economic analysis and the impact of improving technology on delivering more consistent results for scans. For final question, Roger prods James for what's next in this story and asks Louise and Naim what about this conversation influences their work and respective locations today. If you have questions or comments around the LOCATE-NAFLD study or any other ideas addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.Stay Safe and Surf On

Dr. Jason Wright, Editor-in-Chief, Dr. John Fischer, Podcast Editor, and Dr. Emily H. Adhikari, Editorial Board member, review the articles that have been designated as Editors' Picks for the September 2023 issue (risk factors for perinatal transmission of HCV; gynecologic cancer disparities; prediction of SMM and mortality postpartum).

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:Hepatitis B virusDurability of response with bepirovirsenHBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfaHepatitis delta virus96-week follow-up of immediate vs delayed bulevirtideOff-treatment response for lonafarnib + ritonavir ± pegIFN-alfa Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogueHepatitis C virusCollaborative service at opiate substitution treatment clinic to improve linkage to care in IrelandNurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United KingdomFIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of healthPresenter:Stefan Zeuzem, MDProfessor of Medicine Chief, Department of Medicine JW Goethe University Hospital Frankfurt, GermanyLink to full program: https://bit.ly/3JQQj3J

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:How HIV-ASSIST supports ART selection in primary careUpdates to viral hepatitis recommendations including:               CDC HBV screening and testing recommendations             AASLD simplified HCV treatment approach for PWHHIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction CheckerCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Clinical OfficerNational Clinician Consultation CenterProfessorClinical Family Community MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program: bit.ly/3pwaH2Y    

This week, we're sharing a recent chat with Devi Machete, an anarchist involved in the Tijuana mutual aid project known as Contra Viento y Marea Comedor which distributes clothing, medical supplies, meals and packaged food throughout the week near the border with the USA. The project, known for short as El Comedor is launching a free school and art laboratory in May. For the hour, we talk about the migrant caravan in 2018 that gave rise to El Comedor, the self-organized work around the project and resisting the dehumanization of the border through solidarity and community.  Since the US allowed the Trump-Era Title 42 Covid-based restriction on immigrants entering the country to expire and has moved back to Title 8, so in a post-script Devi talks about concerns of a surge at the border and the further difficulties this change creates for migrants and refugees seeking asylum in the north. Facebook: @ContraVientoYMareaComedor Instagram: @ContraVientoYMarea_ElComedor Venmo: @TJRefugee-support Youtube Channel: https://m.youtube.com/channel/UCFY2Pmih9n1hN1b5-6JVq9A/videos Email: contravientoymareacomedor@gmail.com GoFundMe: https://www.gofundme.com/f/migrant-organizers-of-tijuana-need-covid-support soon-to-be-relaunched website: http://www.contravientoymareatj.com/ You can also check out our prior interview with Elements of Mutual Aid directors Leah & Payton to get some visuals of El Comedor, which is a featured project in that docu-series. Announcement Phone In For Shine White All power to the people, As I've pointed out in my previous writings, Hepatitis C kills more Amerikans each day than HIV and sixty other infectious diseases combined, making it the deadliest infectious disease in the United States. It is a viral infection, caused by the Hepatitis C virus (“HCV”) that affects the liver and can result in serious, life-threatening complications. On February 15 of this year blood tests revealed that I had Hepatitis C. In contrast to NCDAC's Clinical Practice Guidelines (CPG) for the treatment of Hepatitis C, I was sent back to my cell, instead of having further blood testing done to determine my fibro-scores. I was provided no further information, other than that I had Hepatitis C and that I would be seen by the facility's healthcare provider at a later date. The following days were mentally exhausting. Only after consulting with a prisoner who was receiving treatment for HCV at the time, did I become aware of the procedures that are in place for evaluating and treating prisoners who have the Hep-C virus. Before treatment can be started, additional blood testing is required to determine one's level of fibrosis.  After becoming aware of the aforementioned, I immediately began to submit sick calls requesting the required blood testing be done to determine my Fib-4 index score. My sick calls went unanswered, only after those of you on the outside made calls to the prison on my behalf was I taken to medical to have the Fib-4 test done. The test results revealed that my Fib-4 score was 5.7, which indicates that I am at risk of cirrhosis, liver disease and/or liver cancer. However, the health care provider has yet to begin my treatment. These scores were revealed to me on March 3, subsequently I've not been assessed by medical personnel since, despite submitting multiple sick-calls due to the complications I am experiencing caused by the hepatitis-c virus. Since early March I have lost approximately 30 pounds, I have various pock-like scores on my lower legs, rashes cover my elbows and knees, and the sharp pains in my lower back and side make it difficult to sleep at night. When I inquire about my treatment, the response I receive is that it is out of their hands. I am firmly convinced that they have no intentions of treating me. Combined with the recent continuation of my term on supermax, it's evident that their intentions are to hold me incommunicado and hope that the hepatitis-c will do what they have been unable to do - silence me! Having to openly admit that I am at the mercy of my overseers infuriates me. I feel helpless and I am scared. I'm witnessing what is being done to Komrade Rashid, I witnessed the late elder Maroon Shoatz languish with cancer for years, Mumia Abu-Jamal continues to suffer from complications caused by hepatitis-c, the names go on and on. I feel as if my twenty-year prison sentence has become a death sentence. I entreat that calls be made and emails be sent on my behalf, demanding that I be treated immediately. Only if pressured by those of you on the outside will these miscreants act with professionalism. I am deeply grateful for the support. I conclude this as I began, Daring to struggle, daring to win All power to the people, Joseph “Shine White” Stewart Below is the contact information for those who should be contacted: NCDAC's Deputy Secretary - Comprehensive Health Services Gary Junker 919-838-4000 gary.junker@dac.nc.gov Chief Deputy Secretary - Rehabilitative and Correctional Services Maggie Brewer 919-733-9313 maggie.brewer@dac.nc.gov Facility's lead nurse J Rowe jacqueline.rowe@dac.nc.gov  . ... . . Featured Tracks: One by J Dilla from Welcome 2 Detroit Instrumental En Caravana by Chiky Rasta Es Épico by Canserbero from Can Vive

In our 100th episode, Marianna sits down with John Faragon to talk about the new plan to end Hepatitis C, or HCV, in the United States. Find out what it is and how you as an HIV care provider can get involved.  --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=DLV5044) 

On this episode, Rich Thayer and Mickey Urdea are interviewing Mike Richey, the Co-Chair of the Board of Directors for the National AIDS Memorial, about the barriers that exist which prevent patients from receiving the healthcare they need, be they geographical, economic, or the result of stigma or prejudice, and the efforts that are being made to circumvent those obstacles. He also shares details on the National AIDS Memorial's "Change The Pattern" initiative and how it is being used in communities across the southern United States as a teaching tool in the fight against HIV/AIDS. Mike Richey has more than 30 years of experience in the healthcare field specializing in diagnostics and personalized medicine. His areas of focus include medical and government affairs, product development, operations, market development, marketing, sales, and executive management. Mr. Richey's primary emphasis over the past 15 years has been in the development and execution of business strategies that fostered the successful creation of a new, high value segment of diagnostics (therametrics). This movement was driven by conclusive scientific analysis, resulting in the clinical evidence needed to substantiate the role that new metrics play in directing therapeutic intervention. After working as a clinical microbiologist at Children's Hospital in Oklahoma City, he joined Abbott Laboratories in 1978, initially working in research and development for the Diagnostics Division and then served in project management, and sales and marketing management roles. Joining Chiron in 1990, Mr. Richey served as Vice President of Marketing in the Diagnostics Division with responsibility for worldwide sales, marketing, and market development for the company's novel HCV and HIV viral load tests. Most recently, he was Co-Founder and President of Tethys Bioscience, where he was also responsible for medical and regulatory affairs, product development, and laboratory and commercial operations. As a consultant, Mr. Richey focuses on research and development, licensing, business and marketing strategies for biotechnology, genomics, and diagnostic companies. He received his BS in Laboratory Technology from the University of Oklahoma in Norman. Learn more about the National AIDS Memorial's "Change The Pattern" quilting project here: https://www.changethepattern.org/

Hepatitis C (HCV) affects around 40,000 people in Alabama, and possibly many more who do not know they have it. Although the disease is largely curable, it affects vulnerable populations that may not get tested or pursue treatment. Ricardo Franco, MD, and David Fettig, MD, discuss their work to eradicate HCV as part of the interdisciplinary ABC Clinic. The doctors discuss the causes for the stubborn prevalence of HCV; their outreach and education to health centers in areas with vulnerable populations; and the unique ability of the ABC Clinic's team of hepatologists and infectious disease experts to treat a range of related viral diseases and liver conditions.

In episode 18 we discuss the Hepatitis C Real Option (HERO) Study about two different models of HCV treatment in people who inject drugs.   Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Heo M, Arnsten J, Meissner P, Karasz A, Mckee MD, Ward JW, Johnson N, Pericot-Valverde I, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Roche J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Page K; HERO Study Group. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1112-1127. https://doi.org/10.1016/S2468-1253(22)00275-8.   Want to learn how to treat HCV? HEPCONNECT AASLD/ISDA Guidelines National Harm Reduction Coalition Hepatitis C Online We also discuss making naloxone nasal spray over the counter, and the increasing number of poisonings from cannabis products. We also want to share some links relevant to episode 16, about in-jail treatment of opioid use disorder. The research was from an organization called JCOIN, which provides resources for those who study opioid use disorder in justice-involved settings. There will also be a new paper coming out by the authors, from the NIH-HEAL Initiative. --------- Episode 18 Credits: Original theme music: composed and performed by Benjamin Kennedy Audio production: Erin McCue Video production: Paul Kennedy Executive Producer: Patrick Beeman A podcast from Ars Longa Media ---------- This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.  The best part of any journal club is the conversation. Send us your comments on Twitter, Facebook, YouTube, email, or join our Facebook group. Email: addictionmedicinejournalclub@gmail.com  Twitter: @AddictionMedJC  Facebook: @AddictionMedJC Facebook Group: Addiction Medicine Journal Club YouTube: addictionmedicinejournalclub Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

On Monday, the Philadelphia Housing Authority made 10,000 spots available on its Housing Choice Voucher waitlist. Formerly know as Section 8, this waitlist has been closed for the past 12 years, and a lottery will determine which Philadelphians can potentially receive affordable housing assistance. Trenae Nuri spoke with Rasheed Ajamu, lifelong Philadelphian and the curator of Phreedom Jawn, about what it was like for his grandmother to live on the waitlist and never get off it.  The application for the HCV waitlist will be open until February 5 at 5:59 p.m.  Read Rasheed's original tweet here. To follow more of Rasheed's work at Phreedom Jawn, check out @phreedomjawn on Instagram and Twitter. Want some more Philly news? Then make sure to sign up for our morning newsletter. We're also on Twitter and Instagram! Follow us @citycastphilly.  Have a question or just want to share some thoughts with the team? Leave us a voicemail or send us a text at 215-259-8170. Learn more about your ad choices. Visit megaphone.fm/adchoices